Bullfrog AI Holdings Inc（BFRG）股票分析BFRGBullfrog AI Holdings Inc

Bullfrog AI Holdings, Inc. is a technology-enabled drug development company. The Company is focused specifically on advanced artificial intelligence/machine learning (AI/ML) analysis of complex data in the advancement of medicine. The Company’s platform technology, bfLEAP, is an analytical AI/ML platform that is a potentially disruptive tool for the analysis of pre-clinical and/or clinical data sets, such as the robust pre-clinical and clinical trial data sets being generated in translational research and development and clinical trial settings. The platform can capture the genetic and physical characteristics of patients in an unbiased manner and contextualize them against other disparate data sources from patients. Its siRNA targets Beta2-spectrin in the treatment of human diseases, such as hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis. Mebendazole is focused on targeting Glioblastoma. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Bullfrog AI Holdings, Inc. (BFRG) is not a strong buy at the moment due to its current price of 0.54, which is down 38.64% year-to-date and 55.73% over the past year. The RSI is at 36.097, indicating it is nearing oversold conditions but still not a clear buy signal. The company has shown some improvement in gross margin, which is now at 49.63%, but it still faces significant net losses, with a net income of -1371530 in the latest quarter. The main risk is the company's ongoing negative earnings, as indicated by a forward P/E of 0 and a price-to-sales ratio of 35.08, suggesting that the stock is overvalued relative to its revenue.